Paper563233
Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine.
Brockman RW and 2 others. Biochem Pharmacol, 1977. Cited by 132 papers, by iCite.
Cite this record
ConductScience Library. Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. Papers, record 563233. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/563233
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Vidarabine | Major topic |
| Animals | |
| Cells, Cultured | |
| DNA, Neoplasm | |
| Leukemia L1210 | |
| Mice | |
| Time Factors |
Source PubMed
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 132 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42239518 | Cellular pharmacology of fludarabine: molecular determinants of transport and metabolism. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42239518 | PubMed |
| 41709524 | Physiologically Based Pharmacokinetic Virtual Twin Approach for Fludarabine Dosing in Pediatric Hematopoietic Stem Cell Transplantation. | CPT Pharmacometrics Syst Pharmacol | 2026 | https://conductscience.org/library/papers/41709524 | PubMed |
| 38856835 | Anticancer potential and structure activity studies of purine and pyrimidine derivatives: an updated review. | Mol Divers | 2025 | https://conductscience.org/library/papers/38856835 | PubMed |
| 33925713 | Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71. | Viruses | 2021 | https://conductscience.org/library/papers/33925713 | PubMed |
| 28624910 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? | J Cancer Res Clin Oncol | 2017 | https://conductscience.org/library/papers/28624910 | PubMed |
| 28108896 | Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors. | Mol Divers | 2017 | https://conductscience.org/library/papers/28108896 | PubMed |
| 24066967 | New insights into the synergism of nucleoside analogs with radiotherapy. | Radiat Oncol | 2013 | https://conductscience.org/library/papers/24066967 | PubMed |
| 21422739 | Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants. | Proc Jpn Acad Ser B Phys Biol Sci | 2011 | https://conductscience.org/library/papers/21422739 | PubMed |
| 19436622 | Fludarabine in the treatment of chronic lymphocytic leukemia: a review. | Ther Clin Risk Manag | 2009 | https://conductscience.org/library/papers/19436622 | PubMed |
| 14576856 | Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. | Oncogene | 2003 | https://conductscience.org/library/papers/14576856 | PubMed |
| 11888330 | Cellular and clinical pharmacology of fludarabine. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/11888330 | PubMed |
| 11417472 | Nucleoside analogues: mechanisms of drug resistance and reversal strategies. | Leukemia | 2001 | https://conductscience.org/library/papers/11417472 | PubMed |
| 9179529 | Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. | Drugs | 1997 | https://conductscience.org/library/papers/9179529 | PubMed |
| 7686467 | Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy. | Drugs | 1993 | https://conductscience.org/library/papers/7686467 | PubMed |
| 7532163 | Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma. | Invest New Drugs | 1994 | https://conductscience.org/library/papers/7532163 | PubMed |
| 7525187 | Evolution of the arabinosides and the pharmacology of fludarabine. | Drugs | 1994 | https://conductscience.org/library/papers/7525187 | PubMed |
| 3327628 | Membrane transport and the antineoplastic action of nucleoside analogues. | Cancer Metastasis Rev | 1987 | https://conductscience.org/library/papers/3327628 | PubMed |
| 2456162 | Phase II trial of fludarabine phosphate (F-Ara-AMP) in patients with advanced breast cancer. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/2456162 | PubMed |
| 2431803 | 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/2431803 | PubMed |
| 2427240 | Pharmacokinetic study of fludarabine phosphate (NSC 312887). | Cancer Chemother Pharmacol | 1986 | https://conductscience.org/library/papers/2427240 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/563233
GET https://conductscience.org/api/papers/v1/563233/cited_by?page=2